Medical Device News Magazine

Global Pain Management Drugs and Devices Market Report 2023 – Rising Demand for Minimally Invasive Pain Solutions –

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

The “Global Market for Pain Management Drugs and Devices” report has been added to’s offering.

The global market for pain management drugs and devices was valued at $80.9 billion in 2022. The market is estimated to grow from $84.6 billion in 2023 at a compound annual growth rate (CAGR) of 5.4% to reach approximately $109.9 billion by the end of 2028. This report segments the global market by product, application and region.

Pain impacts a large number of people across the globe. Pain management drugs and devices help to relieve pain and improve quality of life. The rising prevalence of chronic and neurological disorders and the growing geriatric population are creating many opportunities for players operating in this market.

In addition, technological advancements are serving as a critical factor in the pain management drugs and devices market. Newer medical devices for pain management are minimally invasive, highly efficient and involve lower recovery times for patients. Consequently, this study will provide insights into upcoming trends in the pain management drugs and devices market.

The report provides detailed analysis of the market for pain management drugs and devices. It highlights the current and future market potential of pain management drugs and devices and gives a detailed analysis of the market’s drivers, restraints and challenges. The report also covers market projections for 2028 and provides market rankings for key market players. It also covers the competitive environment and regulatory landscape, and it details the market share of pain management drugs and devices based on product and application. Based on products, the global pain management drugs and devices market is segmented into pharmaceuticals and medical devices. Based on applications, the market is segmented into post-operative pain, neuropathic pain, cancer pain, migraine/headache, musculoskeletal pain and other applications. The report includes company profiles of the key players with detailed information about their business segments, financials, product portfolios and recent developments.

The market has been divided by geography into North America, Europe, Asia-Pacific and the Rest of the world. The North American region comprises countries such as the U.S. and Canada; Europe includes countries Germany, U.K., Italy, France and the Rest of Europe; Asia-Pacific includes countries China, India, Japan and the Rest of Asia-Pacific. For market estimates, data has been provided for 2020 and 2021, which serve as the historical years; 2022 is the base year; and forecast data is given for 2028.

Here is a comparison of a treatment for a disease (in this case, rheumatoid arthritis) that naturally relieves symptoms vs. a treatment for the relief of the pain associated with the disease –

  • Enbrel: Indicated for the treatment of moderate-to-severe rheumatoid arthritis.
  • Celebrex: Indicated for the treatment of the signs and symptoms of osteoarthritis and rheumatoid arthritis and the management of acute pain.

Key Report Highlights

  • An overview of the global market for pain management drugs and devices
  • Estimates of the market size and analyses of global market trends with data from 2020-2023, and projections of compound annual growth rates (CAGRs) through 2028
  • Assessment of pain, history of pain and pain management, and information on physical pain treatment modalities and psychological pain therapies.
  • Coverage of emerging technologies in the pain management market, an assessment of technology advances in opioid drugs, as well as in non-narcotic drugs, which has revolutionized pain management by providing practical alternatives to opioids.
  • Assessment of factors driving the industry’s growth, including market opportunities and restraints
  • Examination of product categories, clinical trials, new regulatory requirements and relevant patents
  • Coverage of market trends in undertreatment issues, professional issues, managed care pain issues, new therapies, product pipelines, generics, pain research and drug delivery
  • Company profiles of major players within the industry, including Abbott Laboratories, AbbVie Inc., Assertio Holdings Inc., Grunenthal GmbH, and Johnson & Johnson

Key Attributes:

Report Attribute Details
No. of Pages 171
Forecast Period 2023 – 2028
Estimated Market Value (USD) in 2023 $84.6 Billion
Forecasted Market Value (USD) by 2028 $109.9 Billion
Compound Annual Growth Rate 5.4%
Regions Covered Global 


Key Topics Covered:

Market Breakdown by Product

  • Pharmaceuticals
  • Narcotic Drugs
  • Non-narcotic Drugs
  • Antimigraine Drugs
  • Anesthesia Drugs
  • Other Drugs
  • Pain Management Devices
  • Neurostimulation Devices
  • Infusion Pumps
  • Ablation Devices

Market Breakdown by Application

  • Musculoskeletal Pain
  • Post-operative Pain
  • Neuropathic Pain
  • Cancer Pain
  • Migraine/Headache
  • Other Applications
  • Burn Pain
  • Dental Pain

Market Breakdown by Region

ESG Development

  • Sustainability in the Pain Management Drugs and Devices Industry: An ESG Perspective
  • Key ESG Issues
  • ESG Ranking
  • Consumer Attitudes toward ESG in the Market for Pain Management Drugs and Devices
  • Case Study

Emerging Technologies

  • Technology Advancements in Opioid Drugs
  • Technology Advancements in Non-narcotic Drugs
  • Technology Advancements in Neuromodulation Devices
  • Technology Advancements in Infusion Pumps
  • Trends in Pain Management
  • Pharmacogenomics
  • AI Pain Management

Clinical Trials and Patent Analysis

  • Clinical Trials Analysis
    • Type of Study
    • Status
    • Phase
    • Region
  • Overview of Patent Analysis
    • Year
    • Top-Ranking Applicant
    • Top-Ranking Patent Holder
    • Jurisdiction

Competitive Intelligence

  • Market for Pain Management Drugs
  • Market for Pain Management Medical Devices
  • Funding
  • Recent Developments by Key Market Players

Company Profiles

  • Abbott Laboratories
  • AbbVie Inc
  • Assertio Holdings
  • AstraZeneca
  • Boston Scientific
  • Eli Lilly
  • Endo International
  • Enovis
  • GlaxoSmithKline
  • Grunenthal
  • Johnson & Johnson
  • Medtronic
  • Novartis International
  • Vertex Pharmaceuticals
  • Viatris

For more information about this report visit

Medical Device News Magazine
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Ultrahuman Announces its App Store ‘PowerPlugs’ with the World’s First AFib Detection Technology on a Smart Ring

Recognizing each individual’s health journey is unique, PowerPlugs enable people to choose and focus on the aspects of their health that matter most. It’s designed for highly personalized health insights, ensuring that every individual can personalize their health tracking to their unique needs and goals.

VisionAir Solutions Celebrates Milestone and New Collaboration

This achievement marks VisionAir Solutions commitment to bringing technological innovation to pulmonary medicine. Since its acquisition by Theken Companies last year, VAS has over doubled its growth and continues to demonstrate industry adoption and the advantages of personalized healthcare.

ArisGlobal Reports | Newest Version of LifeSphere® Regulatory Platform Launches

Ann-Marie Orange, CIO & Global Head of R&D shares, “With more than 35 years of experience in life sciences technology, ArisGlobal is the only technology company offering strong Safety, Regulatory, and Quality Management solutions powered with next-generation cognitive computing, delivering unmatched interoperability across the R&D IT ecosystem. Over the last 18 months ArisGlobal has made significant investment in the strategic acquisitions of Amplexor Life Sciences and SPORIFY, along with technology R&D – and we’re not stopping.”